Smith & Nephew SNATS (NYSE:SNN) Upgraded at Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

Several other research firms have also weighed in on SNN. Canaccord Genuity Group dropped their price objective on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Kepler Capital Markets lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Weiss Ratings cut shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Price Performance

NYSE SNN opened at $30.26 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25. The company has a 50 day simple moving average of $30.30 and a 200-day simple moving average of $32.51. Smith & Nephew SNATS has a 52-week low of $28.56 and a 52-week high of $38.79.

Hedge Funds Weigh In On Smith & Nephew SNATS

A number of hedge funds have recently added to or reduced their stakes in the company. River Road Asset Management LLC raised its position in Smith & Nephew SNATS by 13.8% during the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock valued at $103,996,000 after acquiring an additional 384,926 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Smith & Nephew SNATS by 5.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after acquiring an additional 100,697 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Smith & Nephew SNATS by 44.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider’s stock worth $33,436,000 after purchasing an additional 324,080 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Smith & Nephew SNATS by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after purchasing an additional 575,666 shares during the last quarter. Finally, Todd Asset Management LLC raised its holdings in shares of Smith & Nephew SNATS by 30.2% during the 4th quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider’s stock valued at $30,992,000 after purchasing an additional 219,348 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.